Who are Fidaxomicin tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OPT-80, Fidaxomicin oral suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fidaxomicin-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fidaxomicin tablets — Competitive Intelligence Brief

Fidaxomicin tablets (Fidaxomicin tablets) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrocyclic antibiotic. Area: Infectious Disease.

phase 3 Macrocyclic antibiotic Bacterial RNA polymerase (C. difficile) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fidaxomicin tablets (Fidaxomicin tablets) — Astellas Pharma Europe B.V.. Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fidaxomicin tablets TARGET	Fidaxomicin tablets	Astellas Pharma Europe B.V.	phase 3	Macrocyclic antibiotic	Bacterial RNA polymerase (C. difficile)
OPT-80	OPT-80	Astellas Pharma Inc	phase 3	Macrocyclic antibiotic	Bacterial RNA polymerase
Fidaxomicin oral suspension	Fidaxomicin oral suspension	Astellas Pharma Europe B.V.	phase 3	Macrocyclic antibiotic	Bacterial RNA polymerase (C. difficile)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrocyclic antibiotic class)

Astellas Pharma Europe B.V. · 2 drugs in this class
Astellas Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fidaxomicin tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/fidaxomicin-tablets. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab